CIDP
MCID: CHR070
MIFTS: 57

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 52 58 36 15 37 17
Chronic Inflammatory Demyelinating Polyneuropathy 52 53 58 17
Cidp 52 58
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 71
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 54

Characteristics:

Orphanet epidemiological data:

58
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5213
KEGG 36 H01527
ICD9CM 34 357.81
MeSH 43 D020277
NCIt 49 C84636
ICD10 32 G61.81
ICD10 via Orphanet 33 G61.8
UMLS via Orphanet 72 C0393819
Orphanet 58 ORPHA2932
UMLS 71 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NIH Rare Diseases : 52 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. Other symptoms may include pain, difficulty swallowing (dysphagia ), and double vision (diplopia ). CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids , immunosuppressant drugs, plasma exchange, physical therapy , and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as chronic inflammatory demyelinating polyneuropathy, is related to polyneuropathy and guillain-barre syndrome. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Mycophenolic acid and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and spinal cord, and related phenotypes are fatiguable weakness of proximal limb muscles and areflexia

NINDS : 53 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

KEGG : 36 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a polyneuropathy that is often disabling, with more than 50% of patients reported as having temporary disability, and about 10% eventually becoming persistently disabled. The core clinical features are a chronic progressive or relapsing and remitting, symmetrical, and sensory and motor polyradiculoneuropathy causing weakness of proximal and distal muscles. The etiology is suspected to be of autoimmune origin, and the diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, cerebrospinal fluid (CSF) studies, and pathologic examination. CIDP often responds to immune therapies including corticosteroids, plasma exchange, and high-dose intravenous immunoglobulin (IVIg).

Wikipedia : 74 Chronic inflammatory demyelinating polyneuropathy is an acquired immune-mediated inflammatory disorder... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)
# Related Disease Score Top Affiliating Genes
1 polyneuropathy 31.3 PMP22 MPZ MBP CD59 ALB
2 guillain-barre syndrome 31.2 PMP22 MPZ MBP HLA-DRB1 ALB
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.1 IL17A IL10 IFNG
4 sensory peripheral neuropathy 31.0 PMP22 MPZ ALB
5 hereditary neuropathies 31.0 PMP22 MPZ MBP
6 autoimmune neuropathy 31.0 PMP22 MPZ
7 foot drop 31.0 PMP22 MPZ
8 neurosyphilis 30.9 IL17A IL10
9 myasthenia gravis 30.8 MBP IL10 IFNG
10 chronic graft versus host disease 30.7 IL10 IFNG ALB
11 roussy-levy hereditary areflexic dystasia 30.7 PMP22 MPZ
12 optic neuritis 30.7 MPZ MBP IL10 HLA-DRB1
13 graft-versus-host disease 30.7 IL10 IFNG HLA-DRB1
14 intestinal tuberculosis 30.6 IFNG ALB
15 cutaneous lupus erythematosus 30.6 IL17A IL10 IFNG
16 syphilis 30.5 IL17A HLA-DRB1 ALB
17 discoid lupus erythematosus 30.5 IL10 HLA-DRB1
18 neuromuscular disease 30.5 PMP22 MPZ MBP IL17A IL10 ALB
19 hepatitis a 30.4 IL10 IFNG ALB
20 transverse myelitis 30.4 MBP IL17A IL10
21 cryoglobulinemia 30.4 IL10 IFNG HLA-DRB1
22 mixed connective tissue disease 30.4 IL10 IFNG HLA-DRB1
23 lyme disease 30.3 IL17A IFNB1 HLA-DRB1
24 brucellosis 30.3 IL17A IL10 IFNG
25 viral hepatitis 30.3 IL10 IFNG HLA-DRB1 ALB
26 autoimmune hepatitis 30.2 IL10 HLA-DRB1 ALB
27 chronic mucocutaneous candidiasis 30.2 IL17A IL10 IFNG
28 candidiasis 30.2 IL17A IL10 IFNG
29 neuromyelitis optica 30.1 MBP IL17A HLA-DRB1 CD59
30 acquired immunodeficiency syndrome 30.1 MBP IL10 IFNG ALB
31 sarcoidosis 1 30.0 IFNG HLA-DRB1 CCL5 CCL4
32 radiculopathy 30.0 IL17A IL10 CCL5 CCL4
33 rubella 29.9 IL10 IFNG IFNB1 HLA-DRB1
34 crohn's disease 29.9 IL17A IL10 IFNG HLA-DRB1 ALB
35 immune deficiency disease 29.9 IL10 IFNG CCL5 CCL4
36 myelitis 29.8 MBP IL17A IL10 IFNB1
37 dermatitis 29.8 IL17A IL10 IFNG CCL5
38 hashimoto thyroiditis 29.8 IL17A IL10 IFNG HLA-DRB1
39 optic nerve disease 29.8 MBP IL17A IFNB1 ALB
40 common cold 29.8 IL17A IL10 CCL5 ALB
41 acute disseminated encephalomyelitis 29.7 MPZ MBP IL10 HLA-DRB1 CCL4
42 allergic hypersensitivity disease 29.7 IL17A IL10 IFNG CCL5
43 primary biliary cirrhosis 29.7 IL17A IL10 IFNG HLA-DRB1 ALB
44 connective tissue disease 29.7 IL17A IL10 IFNG HLA-DRB1 ALB
45 neuritis 29.7 PMP22 MPZ MBP IL10 IFNG CCL5
46 peripheral nervous system disease 29.6 PMP22 MPZ MBP IL17A IL10 IFNG
47 psoriasis 29.4 IL17A IL10 IFNG HLA-DRB1 CCL5
48 myeloma, multiple 29.4 PRF1 IL17A IL10 IFNG ALB
49 bacterial infectious disease 29.4 IL17A IL10 IFNG IFNB1 CCL4
50 pulmonary tuberculosis 29.3 IL17A IL10 IFNG HLA-DRB1 CCL4 ALB

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

58 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatiguable weakness of proximal limb muscles 58 31 hallmark (90%) Very frequent (99-80%) HP:0030200
2 areflexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001284
3 paresthesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003401
4 unsteady gait 58 31 hallmark (90%) Very frequent (99-80%) HP:0002317
5 segmental peripheral demyelination/remyelination 58 31 hallmark (90%) Very frequent (99-80%) HP:0003481
6 sensory ataxia 58 31 hallmark (90%) Very frequent (99-80%) HP:0010871
7 motor conduction block 58 31 hallmark (90%) Very frequent (99-80%) HP:0012078
8 falls 58 31 frequent (33%) Frequent (79-30%) HP:0002527
9 difficulty walking 58 31 frequent (33%) Frequent (79-30%) HP:0002355
10 difficulty climbing stairs 58 31 frequent (33%) Frequent (79-30%) HP:0003551
11 hand muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 58 31 occasional (7.5%) Occasional (29-5%) HP:0010833
13 peripheral neuropathy 58 Very frequent (99-80%)
14 decreased nerve conduction velocity 58 Very frequent (99-80%)
15 peripheral demyelination 58 Very frequent (99-80%)
16 sensory impairment 58 Very frequent (99-80%)
17 abnormal nerve conduction velocity 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL5 CD59 IFNB1 IFNG IL10 IL17A
2 homeostasis/metabolism MP:0005376 9.9 ALB CD59 IFNB1 IFNG IL10 IL17A
3 immune system MP:0005387 9.7 ALB CCL5 IFNB1 IFNG IL10 IL17A
4 neoplasm MP:0002006 9.1 ALB IFNB1 IFNG IL10 PRF1 TBX21

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 3 24280-93-1 446541
2
tannic acid Approved Phase 3 1401-55-4
3
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
4
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
5 Immunoglobulin G Phase 3
6 Fingolimod Hydrochloride Phase 3
7 Antitubercular Agents Phase 3
8 Antibiotics, Antitubercular Phase 3
9 Anti-Bacterial Agents Phase 3
10 Pharmaceutical Solutions Phase 2, Phase 3
11
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
12
Levetiracetam Approved Phase 2 102767-28-2 441341
13
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
14
Carmustine Approved, Investigational Phase 2 154-93-8 2578
15
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Melphalan Approved Phase 2 148-82-3 4053 460612
18
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
19
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
20
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
21
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
22
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
23
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
24 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
25
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
26
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
27
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
30
Cortisone Experimental Phase 2 53-06-5 222786
31
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
32 Adjuvants, Immunologic Phase 2
33 interferons Phase 2
34 Interferon-beta Phase 2
35 Trace Elements Phase 2
36 Vitamins Phase 2
37 Micronutrients Phase 2
38 Vitamin B Complex Phase 2
39 Nutrients Phase 2
40 Antioxidants Phase 2
41 Alpha-lipoic Acid Phase 2
42 Vitamin B9 Phase 2
43 Folate Phase 2
44 Thioctic Acid Phase 2
45 Nootropic Agents Phase 2
46 Anticonvulsants Phase 2
47 Autoantibodies Phase 2
48 Anti-Infective Agents Phase 2
49 Antiviral Agents Phase 2
50 Podophyllotoxin Phase 2 518-28-5

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
5 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
6 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
7 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
8 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
10 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
11 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
12 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
16 Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP) Completed NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
17 Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy Completed NCT02638207 Phase 3 NewGam
18 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
19 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
20 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
21 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
23 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
26 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
28 Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety. Completed NCT02637700 Phase 2 Intravenous Immunoglobulin;Placebo
29 A Pilot Study in a Double Blind, Randomized, Placebo-Controlled, Parallel-Group, 16 Week, Trial Design Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (>18 Years of Ages) Suffering From Chronic Idiopathic Axonal Polyneuropathy Completed NCT00156689 Phase 2 levetiracetam
30 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Recruiting NCT03864185 Phase 2
31 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT03861481 Phase 2 Rozanolixizumab
32 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
33 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
34 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
35 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Enrolling by invitation NCT04051944 Phase 2 Rozanolixizumab
36 IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS) Enrolling by invitation NCT03919773 Phase 1, Phase 2 IVIG;Albumin
37 Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial Not yet recruiting NCT04153422 Phase 2 Gammagard IVIG;Placebo
38 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
39 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
40 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS INFUSIONS TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
41 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Unknown status NCT02892890
42 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
43 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
44 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin
45 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
46 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
47 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
48 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
49 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
50 A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs Completed NCT01602848

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

40
T Cells, Bone, Spinal Cord, Liver, Brain, Skin, Lung

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 2292)
# Title Authors PMID Year
1
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
16170091 2005
2
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 54 61
11912115 2002
3
P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
11558784 2001
4
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 54 61
10713353 2000
5
Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
10408537 1999
6
Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. 61
31571349 2020
7
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. 61
31766959 2020
8
Comparison of Lewis-Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre. 61
31574194 2020
9
Low inter-rater reliability of brachial plexus MRI in chronic inflammatory neuropathies. 61
32012299 2020
10
Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. 61
31864140 2020
11
Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. 61
31650551 2020
12
Membrane property changes in most distal motor axons in chronic inflammatory demyelinating polyneuropathy. 61
31650564 2020
13
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). 61
31558790 2020
14
Nerve dysfunction leads to muscle morphological abnormalities in chronic inflammatory demyelinating polyneuropathy assessed by MRI. 61
31573095 2020
15
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. 61
31400231 2020
16
[Intravenous immunoglobulin-induced thrombocytopenia in patient with chronic inflammatory demyelinating polyneuropathy]. 61
31852869 2020
17
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. 61
31922613 2020
18
Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. 61
32006783 2020
19
Chronic inflammatory demyelinating polyneuropathy with tongue fasciculation: A case report. 61
31477466 2020
20
Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy. 61
31348848 2020
21
Progress in Hematopoietic Stem Cell Transplantation for CIDP. 61
32038107 2020
22
Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? 61
31765922 2020
23
Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance. 61
32017808 2020
24
Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. 61
31959710 2020
25
Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: Pitfalls and red flags. 61
31919945 2020
26
Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. 61
31981273 2020
27
MR neurography of lumbosacral nerve roots: Diagnostic value in chronic inflammatory demyelinating polyradiculoneuropathy and correlation with electrophysiological parameters. 61
31923808 2020
28
Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. 61
31325350 2020
29
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. 61
31753915 2020
30
A case of combined central and peripheral demyelination in Zambia. 61
31958671 2020
31
Neuraxial Anesthesia and Lower Extremity Peripheral Nerve Blocks for Ankle Surgery in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. 61
31789825 2020
32
Antiganglioside antibodies in neurological diseases. 61
31726381 2020
33
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. 61
31907599 2020
34
Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents. 61
31531874 2020
35
Nonsystemic vasculitic neuropathy in a patient with IgG-monoclonal gammopathy of undetermined significance: A case report. 61
32000451 2020
36
Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. 61
31941581 2020
37
Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. 61
31827006 2020
38
Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin. 61
31415091 2019
39
Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls. 61
31796460 2019
40
Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. 61
31693967 2019
41
[Chronic inflammatory demyelinating polyneuropathy: Diagnosis and therapeutic update]. 61
31677862 2019
42
Evaluation of Quality of Life in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in Iran. 61
31743250 2019
43
Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. 61
31599454 2019
44
Long-term successful treatment of chronic inflammatory demyelinating polyneuropathy-like polyneuropathy induced by levodopa-carbidopa intestinal gel with intravenous immunoglobulin. 61
31330074 2019
45
A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. 61
31793666 2019
46
Pain in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. 61
31201680 2019
47
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. 61
31740498 2019
48
Ultrastructural Lesions of Nodo-Paranodopathies in Peripheral Neuropathies. 61
31923310 2019
49
Therapeutic plasma exchange in neurological disorders: Experience from a tertiary neuroscience centre. 61
31648858 2019
50
[A women with aplastic anemia developed chronic inflammatory demyelinating polyneuropathy]. 61
31761833 2019

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 IL17A IL10 IFNG IFNB1 CCL5 CCL4
2
Show member pathways
13.19 IL17A IL10 IFNG IFNB1 HLA-DRB1 CCL5
3
Show member pathways
12.59 PRF1 IL17A IL10 IFNG HLA-DRB1 CCL21
4
Show member pathways
12.43 TBX21 IL17A IL10 IFNG HLA-DRB1
5 12.39 TBX21 IL17A IL10 IFNG CCL5
6
Show member pathways
12.18 IL10 CCL5 CCL4 CCL21
7
Show member pathways
12.1 IL17A IL10 IFNG IFNB1
8 12.08 IL10 IFNG IFNB1 HLA-DRB1
9
Show member pathways
11.87 TBX21 IL17A IL10 IFNG
10 11.82 IL10 IFNG CD59
11 11.76 PMP22 MPZ MBP
12
Show member pathways
11.76 TBX21 IFNG HLA-DRB1 CCL4
13 11.6 IL10 IFNG IFNB1
14 11.59 IL17A IFNG HLA-DRB1 CCL5
15 11.46 TBX21 IL17A IL10 IFNG
16 11.38 IL10 CCL5 CCL4
17 11.11 TBX21 IL17A IFNG
18 10.92 IL10 IFNG IFNB1 HLA-DRB1
19 10.87 IL17A IL10 CCL5 CCL4 CCL21
20 10.87 IL17A IL10 IFNG CCL5 CCL4
21 10.7 TBX21 PRF1 IFNG HLA-DRB1

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 IL17A IL10 IFNG IFNB1 CD59 CCL5
2 extracellular region GO:0005576 9.32 PRF1 IL17A IL10 IFNG IFNB1 CD59
3 compact myelin GO:0043218 9.16 PMP22 MBP

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.84 IL17A CCL5 CCL4 CCL21
2 inflammatory response GO:0006954 9.83 IL17A IL10 CCL5 CCL4 CCL21
3 cellular response to interferon-gamma GO:0071346 9.78 CCL5 CCL4 CCL21
4 response to toxic substance GO:0009636 9.77 MBP CCL5 CCL4
5 neutrophil chemotaxis GO:0030593 9.74 CCL5 CCL4 CCL21
6 chemokine-mediated signaling pathway GO:0070098 9.72 CCL5 CCL4 CCL21
7 myelination GO:0042552 9.65 PMP22 MPZ MBP
8 cytokine-mediated signaling pathway GO:0019221 9.65 IL17A IL10 IFNB1 CCL5 CCL4
9 dendritic cell chemotaxis GO:0002407 9.62 CCL5 CCL21
10 positive regulation of T cell migration GO:2000406 9.62 CCL5 CCL21
11 positive regulation of T cell chemotaxis GO:0010820 9.61 CCL5 CCL21
12 negative regulation by host of viral transcription GO:0043922 9.59 CCL5 CCL4
13 immunological synapse formation GO:0001771 9.58 PRF1 CCL21
14 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.58 MBP IL10
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL10 IFNG
16 monocyte chemotaxis GO:0002548 9.54 CCL5 CCL4 CCL21
17 regulation of complement-dependent cytotoxicity GO:1903659 9.52 IL10 CD59
18 positive regulation of natural killer cell chemotaxis GO:2000503 9.51 CCL5 CCL4
19 lymphocyte chemotaxis GO:0048247 9.5 CCL5 CCL4 CCL21
20 positive regulation of killing of cells of other organism GO:0051712 9.49 PRF1 IFNG
21 positive regulation of interleukin-23 production GO:0032747 9.46 IL17A IFNG
22 cellular response to interleukin-1 GO:0071347 9.46 IL17A CCL5 CCL4 CCL21
23 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.4 TBX21 IFNB1
24 response to virus GO:0009615 9.35 TBX21 IFNG IFNB1 CCL5 CCL4
25 immune response GO:0006955 9.23 MBP IL17A IL10 IFNG HLA-DRB1 CCL5

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine receptor binding GO:0042379 9.37 CCL5 CCL21
2 chemokine activity GO:0008009 9.33 CCL5 CCL4 CCL21
3 CCR5 chemokine receptor binding GO:0031730 9.32 CCL5 CCL4
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL4
5 cytokine activity GO:0005125 9.17 IL17A IL10 IFNG IFNB1 CCL5 CCL4
6 CCR chemokine receptor binding GO:0048020 9.13 CCL5 CCL4 CCL21

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....